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medication utilization. Multivariate logistic and linear regression analyses were 
employed. Results: The study sample (n= 32,172) was 15.0±14.5 years old and con-
troller therapy adherence was 32.2%±19.7%. The mean number of SABA claims was 
3.7±3.1; most had 1-5 claims (73.2%), whereas 19.4% had ≥ 6 claims and 7.4% had 
none. The mean number of OCS claims was 1.0±1.4. Patients with ≥ 6 SABA claims 
had 0.7 more OCS claims compared to patients with < 6 claims for SABA (p< 0.0001). 
LTC-adherent (PDC≥ 50%) patients were 96.7% (OR= 1.967;95%CI= 1.826-2.120) more 
likely to have ≥ 6 SABA claims when compared to nonadherent (PDC< 50%) patients 
(p< 0.0001). LTC-adherent patients had 0.11 fewer OCS claims compared to non-
adherent patients (p< 0.0001). The odds of having ≥ 6 SABA claims were higher for 
concurrent dual therapy users, older age, males, African-Americans, and higher 
number of non-study medications (p< 0.0001). Dual therapy users, younger age, 
Hispanic ethnicity, and higher number of non-study medications were associated 
with an increase in OCS use (p< 0.005). ConClusions: Although there was a posi-
tive relationship between LTC adherence and SABA use, increased SABA use served 
as a predictor of increased OCS use, which indicates poor asthma control. Health 
care providers should be aware of SABA use among patients who are both adherent 
and nonadherent to asthma controller medications.
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objeCtives: To determine if there is a significant difference in asthma-related 
health care costs (HCC) and adherence to asthma controllers between patients 
with asthma and comorbid depressive disorder (A+D) vs. patients with asthma 
alone (A). Methods: Texas Medicaid medical and prescription claims from 
1/1/07-10/31/11 were extracted for adults (18-63 years) who had ≥ 2 asthma con-
trollers in the A group, and additionally ≥ 2 antidepressants in the A+D group. 
The index date was the first date of asthma controller use with no previous use 
in the 6-month pre-index period. Patients were followed for 12 months. HCC (2011 
dollars) included asthma-related prescriptions, inpatient, and outpatient costs. 
Proportion of days covered (PDC) was used to assess adherence, and covariates 
included asthma-related pre-index HCC, inpatient visit (Yes/No), numbers of 
outpatient visits and prescriptions, asthma controller class, severity and demo-
graphic characteristics. Descriptive statistics, Wilcoxon test and generalized linear 
model (gamma distribution and log link) were used. Results: Median prescrip-
tion costs (n= 3626) were significantly (p< 0.05) higher, while inpatient+outpatient 
median costs were lower for the A+D vs. A groups ($873.47 vs. $787.28; $47.68 
vs. $73.89, respectively). The median (Mean±SD) asthma-related HCC for A group 
(n= 3400) was not significantly different from the A+D group (n= 226): [($1038.67, 
$1349.85±$1140.16) vs. ($1103.70, $1416.49±$1154.57), p= 0.2198, respectively]. After 
controlling for covariates, regression results showed that compared to A group, 
the A+D group had significantly lower asthma-related HCC (p< 0.0001). Asthma 
controller adherence was significantly and positively related to HCC (p< 0.0001). In 
the A+D group, patients who were more adherent to antidepressants were more 
adherent to asthma controllers. ConClusions: Patients with A+D had significantly 
lower asthma-related HCC than those with A. In A+D, the higher costs of asthma-related 
prescriptions were offset by the lower costs of inpatient+outpatient claims. Patients 
with comorbid asthma and depression should adhere to both asthma controller and 
antidepressant medications.
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objeCtives: Treatment persistence can be a good indicator of drug efficacy and 
tolerability. Inhaled long-acting bronchodilators (e.g., long-acting β 2-agonists 
[LABAs]) are the recommended maintenance treatment in moderate-to-severe 
chronic obstructive pulmonary disease (COPD). Arformoterol and formoterol are 
the only two available nebulized LABAs. There is limited real-world head-to-head 
comparative evidence for nebulized LABAs. The objective is to evaluate the differ-
ence in their treatment persistence. Methods: This retrospective cohort study 
of the PharMetrics Plus claims database included eligible (continuous health plan 
enrollment 180-day pre- and 360-day post-index) patients > 35 years; with ≥ 2 pre-
scriptions of nebulized LABAs between 2008-2011 (first use as index); COPD diagno-
sis (ICD-9-CM 491.x, 492.x, 496.x) with ≥ 2 outpatient or ≥ 1 inpatient claims. Patients 
were excluded if they received nebulized LABA treatment or asthma diagnosis in 
the pre-index period. Persistence was defined as days from index to discontinua-
tion (gap of ≥ 60 days) or end of study. Chi-square and t-test were used to compare 
two cohorts (alpha= 0.05). Cox proportional hazards models were used to evaluate 
discontinuation risk 180- and 360-days post-index as a function of nebulized LABAs, 
age, physician specialty, comorbidities, initiation timing, and pre-index health care 
spending. Results: A total of 1,041 eligible patients (arformoterol= 672, formo-
terol= 369) were included (mean age= 69.4 years, 47.5% females). Compared to formo-
terol patients, arformoterol patients had longer treatment persistence (mean±SD: 
210±133 vs. 192±137 days, p= 0.0356), and lower predicted discontinuation risk 
(hazard ratio [HR]= 0.78 [95% CI 0.65-0.93] in 180-day post-index and HR= 0.87 [95% 
CI 0.75-1.00] in 360-day post-index models). Nebulized LABAs, non-pulmonologist 
prescribing, pre-index depression, and lower pre-index health care spending were 
associated with higher discontinuation risk in both 180- and 360-day Cox models. 
Younger age (35-54 vs. 65+ years) and pre-index diabetes additionally predicted 
higher discontinuation risk in 360-day Cox model. ConClusions: COPD patients 
on arformoterol had a higher treatment persistence compared to formoterol 
patients in this retrospective claims analysis.
was used for the analyses. Results: In the base-case analysis, the standard EAI 
showed an incremental cost of $63 and an incremental effectiveness of negative 
33%, per allergic episode. Overall, the ICER showed a cost saving of approximately 
$190 for the new EAI over the standard EAI, per allergic episode. The sensitivity 
analyses indicated a continuous dominance of the new EAI over plausible range 
of drug costs and injection success rate. These results were reversed when the 
success rate with standard EAI was assumed to be over 50% (base-case value of 
12.5%). ConClusions: Based on the available data and our model assumptions, 
treatment of emergency food-allergy reaction with the new EAI was found to be 
more cost-effective compared to standard EAI. This can be attributed to an improve-
ment in the delivery system resulting in correct injection use.
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objeCtives: Successful asthma management reduces the morbidity and mortality 
associated with the disease as well as the costs associated with treating complica-
tions. Several treatment options exist for asthma management, many that include a 
steroid in combination with a long-acting beta agonist (LABA), which are referred to 
as “controller medications.” The purpose of this project was to estimate the costs and 
effectiveness and to determine the cost-effectiveness of two combination controller 
medications: fluticasone propionate/salmeterol combination (SFC) and mometasone 
furoate/formoterol fumarate dehydrate (MF). Methods: A Markov disease state-
transition model was constructed to estimate the costs and effectiveness of SFC and 
MF. The analysis was conducted from a U.S. health care system’s perspective. Cost 
data for SFC were obtained from a published study evaluating the costs of managing 
asthma exacerbations in the UK in primary and secondary care and cost data for 
MF were derived by averaging out its price from different pharmacy chains available 
online. All costs were converted to 2013 US dollars. Effectiveness data and data on 
transition probabilities were derived from a published clinical trial. The model was 
run over a 12-week period using TreeAge Pro 2013. Results: The cost associated with 
SFC treatment was estimated to be $1244 with 3 asthma controlled weeks and the cost 
associated with MF was $2884 with 1 asthma controlled week. The results showed that 
treatment with MF was dominated by SFC. ConClusions: This preliminary study 
shows that asthma management with SFC offers more treatment advantage and costs 
less compared to MF, therefore is more cost-effective than MF in asthma management.
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objeCtives: Web-based interventions are promising smoking cessation tools. We 
are testing the effectiveness of Transition2Quit, a tailored web-based and e-mes-
sage program for hospitalized smokers, versus usual care (minimal advice through 
non-tailored printed materials). We present data on resources to implement 
Transition2Quit. Methods: Interventionists approached smokers during hospitali-
zations to register and orient them to the website (onsite registration). Staff made 
≥ 5 attempts at a follow-up contact 7-14 days post-discharge. Through the website, 
we tracked follow-up calls and web activity. Interventionists recorded start and fin-
ish times of their activities. Results: Of 737 smokers, 54.4% were male, 27.4% had 
cancer, 29.2% heart disease/stroke, 13.3% lung disease, 15.6 surgery or wound healing, 
and the rest other conditions. Mean age was 41.6 years. Onsite registration lasted 
8-41 minutes (mean 17.6, median 16, SD 8.23), usual care 0-6 minutes (mean 2, SD 1). 
Interventionists attempted 2.9 calls per person (SD 1.9, max 9). 129 participants could 
not be reached due to disconnected phones, death, or ≥ 5 call attempts. For 43.4% ≥ 1 
call was placed on weekends, for 69% in the evening. Follow-up calls lasted an average 
of 2.4 minutes (median 3, SD 0.9). 700 participants accessed the website 15.4 times 
(SD 17.1), on 1.98 days (SD 3.39), and accessed 5.39 pages (SD 4.06). Women were more 
likely to access the website than men (16.9 vs 14.2, p 0.04). Participants with heart dis-
ease accessed 18.4 times (SD 23.6), with cancer 15.4 (SD 13.8), with surgery or wound 
healing 15.2 (SD 13.0), with lung disease 12.9 (SD 10.7), with other condition 12.2 (SD 
14.5) (p= 0.018). ConClusions: Transition2Quit required minimal staff resources: 
to better inform dissemination, further understanding on how requirements vary 
depending on populations’ characteristics (e.g., age, health condition) is needed. The 
website content may need to be better tailored to men and lung disease patients.
ReSPIRatORy-Related dISORdeRS – Patient-Reported Outcomes & Patient 
Preference Studies
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objeCtives: To determine if there is a relationship between asthma long-term 
controller (LTC) adherence and short-acting β 2-agonist (SABA)/oral corticosteroid 
(OCS) use. Methods: Texas Medicaid prescription claims from 7/1/2008-8/31/2010 
for continuously enrolled patients aged 5-63 years diagnosed with asthma (ICD-9 
493.xx) and who had persistent asthma were included in this retrospective database 
study. Patients were followed for one year after the first (index) asthma controller 
prescription. The primary outcomes were SABA use (dichotomous: < 6 vs. ≥ 6) and 
OCS use (continuous). The primary independent variable was adherence [Proportion 
of Days Covered (PDC)] to asthma LTCs. Covariates included demographics and 
